Myelodysplastic syndrome and its therapeutic options: transplantation, supportive therapy and other treatments
Myelodysplastic syndrome and its therapeutic options: transplantation, supportive therapy and other treatments
DOI:
https://doi.org/10.51473/rcmos.v1i1.2025.1152Keywords:
Myelodysplastic Syndrome, Hematologic Disorders, Hematologic Therapies.Abstract
Myelodysplastic Syndrome (MDS) is a group of hematologic disorders characterized by dysfunction in the formation of blood cells in the bone marrow, resulting in anemia, leukopenia, and thrombocytopenia. The condition can vary in severity, from asymptomatic forms to those that progress to acute leukemia. Treatment for MDS depends on several factors, such as the severity of the disease, the patient's age, and the presence of comorbidities. The main therapeutic options include hematopoietic stem cell transplantation, which offers a potential cure but carries a high risk of complications. Supportive therapy, such as blood transfusions and colony-stimulating agents, aims to alleviate symptoms and improve patients' quality of life. Furthermore, pharmacological treatments such as DNA methyltransferase inhibitors have shown benefits in some cases. The management of MDS requires an individualized approach, considering the benefits and risks of each therapeutic option. Disease progression and response to treatment can be unpredictable, making continuous monitoring and adjustment of therapeutic strategies as needed essential.
Downloads
References
ARÊDES, L. R, et al . USO DE CAR-T CELL NO TRATAMENTO DA LEUCEMIA
MIELOIDE AGUDA: REVISÃO INTEGRATIVA. Hematology, Transfusion and Cell Therapy, v. 46, p. S361-S362, 2024. DOI: https://doi.org/10.1016/j.htct.2024.09.607
ARRUDA, Alcinia Braga de Lima et al. TRATAMENTO DA SÍNDROME MIELODISPLÁSICA EM IDOSOS: UMA REVISÃO INTEGRATIVA. In: ENVELHECIMENTO HUMANO: DIFERENTES NUANCES E ESTÁGIOS-VOLUME
Editora Científica Digital, 2024. p. 214-233.
ARAUJO, A. A. et al. APLASIA DE MEDULA ÓSSEA CONSTITUCIONAL ASSOCIADA À DISCERATOSE CONGÊNITA COM MUTAÇÃO EM TINF2–USO DE
DANAZOL. Hematology, Transfusion and Cell Therapy, v. 45, p. S600, 2023. DOI: https://doi.org/10.1016/j.htct.2023.09.1095
CUNHA, J. V. M. et al. TRANSPLANTE ALOGÊNICO EM PACIENTES COM ANEMIA DE FANCONI: UMA REVISÃO DE LITERATURA. Hematology,
Transfusion and Cell Therapy, v. 46, p. S671, 2024. DOI: https://doi.org/10.1016/j.htct.2024.09.1125
COSTA, E. Y. S. et al. INTERVENÇÕES FISIOTERAPÊUTICAS NO MANEJO DE COMPLICAÇÕES EM PACIENTES PÓS-TRANSPLANTE DE MEDULA ÓSSEA.
Hematology, Transfusion and Cell Therapy, v. 46, p. S977, 2024. DOI: https://doi.org/10.1016/j.htct.2024.09.1662
CHEN LIANG, Tzu Hua. Predisposición germinal en pacientes adultos diagnosticados de síndrome mielodisplásico a una edad temprana sin disfunción orgánica previa. Proyecto de investigación:, 2022.
CAMPOS, S. E. V. et al. COMBINAÇÃO BEM SUCEDIDA DE AZACITIDINA E VENETOCLAX: MUDANDO PARADIGMAS NO TRATAMENTO DE LEUCEMIA
MIELOIDE AGUDA E SÍNDROME MIELODISPLÁSICA. Hematology, Transfusion and Cell Therapy, v. 44, p. S635-S636, 2022. DOI: https://doi.org/10.1016/j.htct.2022.09.1091
DA SILVA BOMFIM, Vitoria Vilas Boas et al. Transplante de medula óssea em tratamentos de pacientes com leucemia aguda: revisão integrativa da literatura. Research, Society and Development, v. 11, n. 17, p. e90111738574-e90111738574, 2022. DOI: https://doi.org/10.33448/rsd-v11i17.38574
JUNIOR, I. O. F. et al. PERFIL EPIDEMIOLÓGICO E SOBREVIDA GLOBAL DOS PACIENTES PORTADORES DE SÍNDROME DE 5Q-NA ERA PÓS
LENALIDOMIDA: EXPERIÊNCIA DE ÚNICO CENTRO. Hematology, Transfusion and Cell Therapy, v. 43, p. S188, 2021. DOI: https://doi.org/10.1016/j.htct.2021.10.318
PAIVA, MJAME. TRATAMENTO EPIGENÉTICO ONCO-HEMATOLÓGICO: UMA REVISÃO DE LITERATURA COM FOCO NA LEUCEMIA MIELOIDE AGUDA.
Hematology, Transfusion and Cell Therapy, v. 45, p. S284-S285, 2023. DOI: https://doi.org/10.1016/j.htct.2023.09.564
PIAZERA, F. Z. et al. ANÁLISE SOBRE EXPERIÊNCIA DO USO DE IBRUTINIBE EM PACIENTES BRASILEIROS SUBMETIDOS AO TRANSPLANTE DE CÉLULAS TRONCO HEMATOPOÉTICAS (TCTH) COM DOENÇA ENXERTO VERSUS HOSPEDEIRO CRÔNICA (CGVHD) REFRATÁRIA/DEPENDENTE DE ESTEROIDES (CTC): SÉRIE DE CASOS DE CENTRO ÚNICO. Hematology,
Transfusion and Cell Therapy, v. 46, p. S1190, 2024. DOI: https://doi.org/10.1016/j.htct.2024.09.2082
PULGARIN, et al. Síndrome mielodisplásico: aspectos básicos y abordaje diagnóstico. Revista colombiana de hematología y oncología, v. 8, n. 1, p. 90-106, 2021. DOI: https://doi.org/10.51643/22562915.120
MARTINS, Henrique Girão et al. Síndrome mielodisplásica variante hipoplásica: análise estatística no serviço de transplante de medula óssea do Hospital Universitário Walter Cantídio. 2022. DOI: https://doi.org/10.20513/2447-6595.2022v62n1e43560p1-7
MANCUSO, R. I. et al. EFEITOS IMUNOMODULADORES DO ARTESUNATO EM UM MODELO ANIMAL DE SÍNDROME MIELODISPLÁSICA. Hematology,
Transfusion and Cell Therapy, v. 46, p. S444-S445, 2024. DOI: https://doi.org/10.1016/j.htct.2024.09.747
ROSA, V. M. et al. SINDROME MIELODISPLÁSICA COM MONOSSOMIA DO SETE EVOLUINDO COM LEUCEMIA AGUDA DE FENÓTIPO MISTO: RELATO DE CASO.
Hematology, Transfusion and Cell Therapy, v. 46, p. S709, 2024. DOI: https://doi.org/10.1016/j.htct.2024.09.1190
SALGARELLO, L. S. et al. CRITÉRIOS PROGNÓSTICOS DE EVOLUÇÃO DE SÍNDROME MIELODISPLÁSICA PARA LEUCEMIA MIELOIDE AGUDA: REVISÃO
SISTEMÁTICA. Hematology, Transfusion and Cell Therapy, v. 46, p. S443-S444, 2024. DOI: https://doi.org/10.1016/j.htct.2024.09.746
SIELFELD, J. P. et al. TRATAMENTO DE SÍNDROME MIELODISPLÁSICA DE ALTO RISCO COM AZACITIDINA E TRANSPLANTE DE MEDULA ÓSSEA
HAPLOIDÊNTICO: RELATO DE UM CASO. Hematology, Transfusion and Cell Therapy, v. 43, p. S188-S189, 2021. DOI: https://doi.org/10.1016/j.htct.2021.10.319
VIEL, F. et al. SÍNDROME MIELODISPLÁSICA EM ADULTOS JOVENS: REVISÃO
E ANÁLISE CRÍTICA DA LITERATURA. Hematology, Transfusion and Cell Therapy, v. 46, p. S452, 2024. DOI: https://doi.org/10.1016/j.htct.2024.09.760
Downloads
Additional Files
Published
Issue
Section
Categories
License
Copyright (c) 2025 Joara Predebom Flores Teixeira (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
